This paper is in the following e-collection/theme issue:

Psychiatry (76) Registered Report (684) Depression and Mood Disorders; Suicide Prevention (1531) Anxiety and Stress Disorders (1199) Gastroenterology and Hepatology (82)

Published on in Vol 11, No 1 (2022): Jan-Jun

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/32234, first published .
Microbial Ecosystem Therapeutic-2 Intervention in People With Major Depressive Disorder and Generalized Anxiety Disorder: Phase 1, Open-Label Study

Microbial Ecosystem Therapeutic-2 Intervention in People With Major Depressive Disorder and Generalized Anxiety Disorder: Phase 1, Open-Label Study

Microbial Ecosystem Therapeutic-2 Intervention in People With Major Depressive Disorder and Generalized Anxiety Disorder: Phase 1, Open-Label Study

Authors of this article:

Arthi Chinna Meyyappan1, 2, 3 Author Orcid Image ;   Evan Forth1, 2, 3 Author Orcid Image ;   Roumen Milev1, 2, 3 Author Orcid Image
Article Authors Cited by (11) Tweetations (9) Metrics

Journals

  1. Ceolin G, Breda V, Koning E, Meyyappan A, Gomes F, Moreira J, Gerchman F, Brietzke E. A Possible Antidepressive Effect of Dietary Interventions: Emergent Findings and Research Challenges. Current Treatment Options in Psychiatry 2022;9(3):151 View
  2. Teixeira A, Martins L, Berk M, Bauer M. Severe psychiatric disorders and general medical comorbidities: inflammation-related mechanisms and therapeutic opportunities. Clinical Science 2022;136(17):1257 View
  3. Liu L, Wang H, Chen X, Xie P. Gut microbiota: a new insight into neurological diseases. Chinese Medical Journal 2023;136(11):1261 View
  4. MacKay M, Yang B, Dursun S, Baker G. The Gut-Brain Axis and the Microbiome in Anxiety Disorders, Post-Traumatic Stress Disorder and Obsessive-Compulsive Disorder. Current Neuropharmacology 2024;22(5):866 View
  5. Khaledi M, Sameni F, Gholipour A, Shahrjerdi S, Golmohammadi R, Gouvarchin Ghaleh H, Poureslamfar B, Hemmati J, Mobarezpour N, Milasi Y, Rad F, Mehboodi M, Owlia P. Potential role of gut microbiota in major depressive disorder: A review. Heliyon 2024;10(12):e33157 View
  6. McMillan A, Theriot C. Bile acids impact the microbiota, host, and C. difficile dynamics providing insight into mechanisms of efficacy of FMTs and microbiota-focused therapeutics. Gut Microbes 2024;16(1) View
  7. Bahmani M, Mehrtabar S, Jafarizadeh A, Zoghi S, Heravi F, Abbasi A, Sanaie S, Rahnemayan S, Leylabadlo H. The Gut Microbiota and Major Depressive Disorder: Current Understanding and Novel Therapeutic Strategies. Current Pharmaceutical Biotechnology 2024;25(16):2089 View
  8. Rågård N, Baumwall S, Paaske S, Hansen M, Høyer K, Mikkelsen S, Erikstrup C, Dahlerup J, Hvas C. Validation methods for encapsulated faecal microbiota transplantation: a scoping review. Therapeutic Advances in Gastroenterology 2025;18 View
  9. Sah A, Singewald N. The (neuro)inflammatory system in anxiety disorders and PTSD: Potential treatment targets. Pharmacology & Therapeutics 2025;269:108825 View
  10. Chinna Meyyappan A, Sgarbossa C, Bromley H, Forth E, Müller D, Vazquez G, Cabrera C, Milev R. The Safety and Efficacy of Microbial Ecosystem Therapeutic-2 in People With Major Depression – A Phase 2, Double-Blind, Placebo-Controlled Study: Clinical Results: Innocuité et efficacité du traitement de l'écosystème microbien (met–2) dans la dépression majeure – une étude de phase 2 à double insu contrölée par placebo : résultats cliniques. The Canadian Journal of Psychiatry 2025 View
  11. Wu S, Zhang Y, Lu Y, Yin Y, Yang C, Tang W, Song T, Tao X, Wang Q. Vascular depression: A comprehensive exploration of the definition, mechanisms, and clinical challenges. Neurobiology of Disease 2025;211:106946 View